News

Filter

Current filters:

PharmaceuticalAmylin

1 to 9 of 42 results

Genesis 2013: Secrets of B-MS and AstraZeneca Amylin deal revealed

Genesis 2013: Secrets of B-MS and AstraZeneca Amylin deal revealed

16-12-2013

Secrets of how Bristol-Myers Squibb and AstraZeneca arranged a behind-the-scenes deal to buy Amylin were…

AmylinAstraZenecaBristol-Myers SquibbDiabetesInterviewsLegalMergers & AcquisitionsPharmaceuticalUKUSA

Briefs: Pfizer $142 million fine upheld; Bristol-Myers shuts Amylin facility

05-04-2013

The US Court of Appeals in Boston has upheld a $142.1 million damage award to Kaiser Foundation Health…

AmylinBristol-Myers SquibbLegalManagementMarkets & MarketingNeurontinNorth AmericaPfizerPharmaceutical

Head-to-head trial of diabetes drugs Victoza and Bydureon yields mixed results

08-11-2012

A direct, head-to-head comparison of two of the newer treatments available for type 2 diabetes yielded…

AmylinBydureonDiabetesEli LillyNovo NordiskPharmaceuticalResearchVictoza

South Korea's type 2 diabetes drug market to grow to over $550 million in 2016

23-10-2012

The type 2 diabetes therapeutic market in South Korea will grow 11% annually from $330 million in 2011…

AmylinAsia-PacificBydureonDiabetesJanumetJanuviaMarkets & MarketingMerck & CoNovo NordiskPharmaceuticalVictoza

AstraZeneca and Bristol-Myers complete diabetes alliance expansion; Lilly revises guidance

10-08-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) said yesterday that, following Bristol-Myers Squibb's…

AmylinAstraZenecaBiotechnologyBristol-Myers SquibbDiabetesEli LillyFinancialLicensingPharmaceutical

Amylin seduced by $5.3 billion bid from Bristol-Myers; AstraZeneca chips in for share of the action

02-07-2012

Having rejected a media reported $22 a share offer from the company earlier this year, US biotech firm…

AmylinAstraZenecaBiotechnologyBristol-Myers SquibbBydureonByettaDiabetesEli LillyMergers & AcquisitionsPharmaceutical

1 to 9 of 42 results

COMPANY SPOTLIGHT

Menarini

Back to top